Scarica l'app Stockscreener
44.95
7.28%
-3.53
Dopo l'orario di chiusura:
44.71
-0.24
-0.53%
Precedente Chiudi:
$48.48
Aprire:
$48.28
Volume 24 ore:
438.39K
Relative Volume:
0.80
Capitalizzazione di mercato:
$1.24B
Reddito:
$17.16M
Utile/perdita netta:
$-163.62M
Rapporto P/E:
-7.3931
EPS:
-6.08
Flusso di cassa netto:
$-121.61M
1 W Prestazione:
-10.28%
1M Prestazione:
+9.90%
6M Prestazione:
+88.23%
1 anno Prestazione:
+236.45%
Intervallo 1D:
$44.80
$48.57
Intervallo di 1 settimana:
$44.80
$52.47
Portata 52W:
$12.21
$52.47
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Confronta ANAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
44.95 | 1.34B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
AnaptysBio, Inc. $ANAB Shares Sold by Voya Investment Management LLC - MarketBeat
Is AnaptysBio Inc AN6 a good long term investmentTrading Volume Surges & High Profit Investment Ideas - earlytimes.in
New Highs: Is AnaptysBio Inc stock a safe haven assetEarnings Growth Report & AI Forecasted Stock Moves - moha.gov.vn
This biotech stock has more than tripled in 2025, but red flags are waving - MSN
AnaptysBio (NASDAQ:ANAB) Stock Price Down 4%Should You Sell? - MarketBeat
Trade Alert: Independent Director Of AnaptysBio J. Ware Has Sold Stock - simplywall.st
AnaptysBio (NASDAQ:ANAB) Hits New 12-Month HighTime to Buy? - MarketBeat
AnaptysBio stock hits 52-week high at $51.58 - Investing.com
AnaptysBio stock hits 52-week high at $51.58 By Investing.com - Investing.com Canada
Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 3,900 Shares of Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Sells $75,000.00 in Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) CFO Dennis Mulroy Sells 10,000 Shares - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 10,000 Shares - MarketBeat
Anaptysbio Insider Sold Shares Worth $510,000, According to a Recent SEC Filing - marketscreener.com
Anaptysbio Insider Sold Shares Worth $500,000, According to a Recent SEC Filing - marketscreener.com
AnaptysBio Executives and Director Execute Stock Sales - TradingView — Track All Markets
AnaptysBio Executives Sell Shares - TradingView — Track All Markets
AnaptysBio (NASDAQ: ANAB) CMO reports option exercise and stock sale - Stock Titan
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is AnaptysBio Inc. stock a buy in volatile marketsDip Buying & AI Enhanced Market Trend Forecasts - Улправда
AnaptysBio sets $100M stock repurchase plan - MSN
How AnaptysBio Inc. (AN6) stock trades under stagflationJuly 2025 Spike Watch & Smart Allocation Stock Reports - Улправда
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving - Yahoo Finance
Will AnaptysBio Inc. stock reach Wall Street targetsQuarterly Market Review & Consistent Income Trade Recommendations - DonanımHaber
What dividend safety score for AnaptysBio Inc. stockNew Guidance & Consistent Growth Stock Picks - Bölüm Sonu Canavarı
Is AnaptysBio Inc. stock recession proofIPO Watch & Capital Efficiency Focused Strategies - DonanımHaber
AnaptysBio, Inc. $ANAB Shares Bought by Assenagon Asset Management S.A. - MarketBeat
AnaptysBio (STU:AN6) EV-to-OCF : -6.99 (As of Dec. 19, 2025) - GuruFocus
AnaptysBio (NASDAQ:ANAB) Sets New 1-Year HighWhat's Next? - MarketBeat
AnaptysBio (NASDAQ:ANAB) CFO Sells $705,266.25 in Stock - MarketBeat
Eric Loumeau Sells 10,000 Shares of AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 12,500 Shares - MarketBeat
Avoiding Lag: Real-Time Signals in (ANAB) Movement - Stock Traders Daily
AnaptysBio (ANAB) CFO option exercise and Rule 10b5-1 share sale detailed - Stock Titan
AnaptysBio stock hits 52-week high at 47.95 USD - Investing.com
AnaptysBio stock hits 52-week high at 47.95 USD By Investing.com - Investing.com Nigeria
Squarepoint Ops LLC Invests $2.43 Million in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio (ANAB) Receives a Buy from Wells Fargo - The Globe and Mail
AnaptysBio (ANAB) Price Target Lowered by Barclays, Maintains Ov - GuruFocus
Officer Loumeau Files To Sell 12,500 Of AnaptysBio Inc [ANAB] - TradingView — Track All Markets
Vanda submits BLA to FDA for generalized pustular psoriasis drug By Investing.com - Investing.com Nigeria
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - marketscreener.com
Vanda (Nasdaq: VNDA) seeks priority FDA review of BLA for GPP drug imsidolimab - Stock Titan
JP Morgan maintains a sell rating on GSK plc (GSK) - MSN
683 Capital Management LLC Has $11.10 Million Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
Camber Capital Management LP Sells 625,000 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio stock hits 52-week high at 46.57 USD - Investing.com
AnaptysBio stock hits 52-week high at 46.57 USD By Investing.com - Investing.com Canada
Stifel Nicolaus Lowers AnaptysBio (NASDAQ:ANAB) Price Target to $56.00 - MarketBeat
AnaptysBio (ANAB) Analyst Rating Update: Stifel Lowers Price Tar - GuruFocus
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment - BioSpace
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):